论文部分内容阅读
目的研究奥扎格雷钠和降栓酶(腹蛇抗检酶)联合治疗脑血栓患者的临床效果。方法 64例脑血栓患者作为研究对象,随机分为试验组和对照组,每组32例。对照组单独采用奥扎格雷钠治疗,试验组联合应用降栓酶治疗。观察患者的临床疗效及血脂变化情况。结果试验组患者治疗总有效30例(93.8%),高于对照组的23例(71.9%),差异有统计学意义(P<0.05);两组患者治疗前血脂指标差异无统计学意义(P>0.05),治疗后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)明显降低、高密度脂蛋白胆固醇(HDL-C)明显提高,且试验组指标优于对照组,差异具有统计学意义(P<0.05)。结论奥扎格雷钠和降栓酶联合用药治疗脑血栓疗效显著高于奥扎格雷钠单独治疗,且联合用药不良反应低,安全可靠,可大量应用于脑血栓的临床治疗。
Objective To study the clinical efficacy of sodium ozagrel and thromboxanin in the treatment of patients with cerebral thrombosis. Methods Sixty-four patients with cerebral thrombosis were randomly divided into experimental group and control group, with 32 cases in each group. The control group was treated with ozagrel sodium alone, and the experimental group was treated with desfibonectin. To observe the clinical efficacy of patients and changes in blood lipids. Results The total effective rate of treatment group was 30 cases (93.8%), which was higher than that of the control group (71.9%), the difference was statistically significant (P <0.05). There was no significant difference between the two groups before treatment (P> 0.05). After treatment, TC, TG and LDL-C were significantly decreased and HDL-C significantly increased Better than the control group, the difference was statistically significant (P <0.05). Conclusion The combination of ozagrel and thromboxanin in the treatment of cerebral thrombosis was significantly higher than that of ozagrel sodium alone, and the combination therapy with low adverse reactions, safe and reliable, can be widely used in the clinical treatment of cerebral thrombosis.